ReviewTherapeutic advances in medical oncology2026
Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions.
Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors arising from neuroendocrine cells located in various organs, most commonly the gastrointestinal tract and pancreas, followed by the lungs. According to the 2022 World Health Organization (WHO) classification, NENs are categorized into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, with NETs further subdivided into G1, G2, and G3 according to the Ki-67 index. Among these, gastroenteropancreatic NENs (GEP-NENs) account for most cases and have become an important area of therapeutic investigation. As understanding of the disease has deepened, various treatment modalities have been developed, and treatment strategies tailored to specific subtypes have become increasingly complex. Currently, the treatment selection for GEP-NENs is largely based on the WHO classification. Hormonal therapy, molecular-targeted therapy, cytotoxic chemotherapy, and peptide receptor radionuclide therapy are standard treatment options for unresectable GEP-NETs, whereas cytotoxic chemotherapy remains the standard of care for GEP-NECs. However, therapeutic development and clinical outcomes remain unsatisfactory in unresectable NENs because of their rarity, highlighting the need for further therapeutic advancements in systemic therapy. In this review, we summarize the current landscape of systemic therapies, recent therapeutic advances, and their underlying biological mechanisms in GEP-NENs, while discussing the ongoing challenges and future directions in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.